21:41 , Jul 25, 2019 |  BC Innovations  |  Emerging Company Profile

Axial: targeting gut microbe metabolites for CNS disorders

Microbiome play Axial is using small molecules to treat the gut end of the gut-brain axis for Parkinson's disease and autism. Co-founder and CEO David Donabedian told BioCentury that Axial Biotherapeutics Inc. believes that the...
22:33 , May 2, 2019 |  BC Innovations  |  Product Development

Evelo breaks from the microbiome pack with non-colonizing bugs

While most companies developing bugs as drugs want their microbes to flourish in hosts, Evelo is designing microbial candidates that exert therapeutic effects without colonizing, replicating or metabolizing -- acting more like biologics than live...
02:31 , Mar 15, 2019 |  BC Innovations  |  Product Development

The microbiome universe in two maps

In its “big bang” over the last decade, the universe of microbiome therapeutics has expanded far beyond its origins of fecal transplants, used primarily for C. difficile . Mapping biotech activity reveals a broadening range...
03:23 , Mar 1, 2019 |  BC Innovations  |  Product R&D

Mapping microbiome manufacturing

Microbiome companies have been squeezed by the scarcity of contract manufacturers willing to work with tough bacterial strains. While contractors are starting to engage, it could take a big clinical win for them to fully...
22:41 , Sep 13, 2018 |  BC Week In Review  |  Clinical News

4D's MRx0004 improves inflammation in asthma model

4D Pharma plc (LSE:DDDD) said once-daily oral MRx0004 protected against airway inflammation by decreasing infiltration of both neutrophils and eosinophils in the lung bronchoalveolar lavage fluid of a house dust mite mouse model of severe...
02:35 , Jul 15, 2017 |  BioCentury  |  Finance

Guts and ambition

With an additional $50 million in funding and plans to start 5-10 clinical trials of monoclonal microbials in 2018, Evelo Biosciences Inc. is shaping up to be one of the most ambitious of the microbiome...
22:39 , Apr 7, 2017 |  BioCentury  |  Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
00:30 , Jan 13, 2017 |  BC Innovations  |  Targets & Mechanisms

Gut control

As evidence mounts linking obesity to the microbiome, three independent studies have identified separate ways of harnessing gut microbiota to treat the condition. The spectrum of approaches, which involve a bacterial protein, a bacterial species...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Thetanix: Phase I started

4D Pharma began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate oral Thetanix in about 20 patients ages 16-18. In the first part, 10 patients will receive a single dose of Thetanix. In the...
07:00 , May 9, 2016 |  BioCentury  |  Product Development

Community organizers

With new papers published by the day and a flurry of big-dollar deals and financings, it's hard to separate the signal from the noise in the microbiome space. The space has become so hot that...